Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Pharma says Collection of Accounts Receivable is Improving

publication date: Sep 22, 2008

China Pharma Holdings now says its Q3 results “could” show a positive cash flow. Last week, the company reported it expects a 40% increase in revenue during the period. China Pharma is doing well in terms of growth and profitability, but as we have reported over the past year, its growing Accounts Receivable numbers have kept the company from truly prospering. Now, China Pharma has released a statement that says new collection policies are starting to have a positive effect. More details...

Stock Symbol: (OTCBB: CPHI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here